Elenita Rosado, MD
Geriatric Medicine · Houston, TXNPI 1144403486
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 75 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,025 and has fallen 87.6% since, to $127 in 2024.
Across 75 payments — averaging $16.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$168
- Teva Pharmaceuticals USA, Inc.$144
- AstraZeneca$129
- Sanofi$127
- AbbVie$104
- Amgen$100
- plus $470 from 11 others
What the payments were for
- Food & beverage$1,242100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 10 | $168 |
| Teva Pharmaceuticals USA, Inc. | 10 | $144 |
| AstraZeneca | 9 | $129 |
| Sanofi | 1 | $127 |
| AbbVie(2 entities) | 6 | $104 |
| Amgen | 5 | $100 |
| GSK | 6 | $88 |
| Johnson & Johnson | 6 | $73 |
| Pfizer | 5 | $60 |
| Lilly USA, LLC | 5 | $59 |
| Novo Nordisk | 3 | $42 |
| Theratechnologies Inc. | 1 | $38 |
| Astellas Pharma US Inc | 3 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Genentech USA, Inc. | 1 | $19 |
| Nalpropion Pharmaceuticals LLC | 1 | $12 |
| Novartis | 1 | $11 |
How this compares
$1,242 in reported general payments places this provider in the 80th percentile of 275 geriatric medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 49 | $52,872 |
| OzempicSemaglutide | 47 | $42,046 |
| JardianceEmpagliflozin | 28 | $37,403 |
| EliquisApixaban | 60 | $31,217 |
| RybelsusSemaglutide | 13 | $28,771 |
| XareltoRivaroxaban | 50 | $25,668 |
| EntrestoSacubitril/Valsartan | 22 | $18,242 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $14,772 |
| MyrbetriqMirabegron | 17 | $13,834 |
| JanuviaSitagliptin Phosphate | 14 | $10,239 |
| TradjentaLinagliptin | 17 | $7,736 |
| Atorvastatin Calcium | 436 | $5,969 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $4,880 |
| Glucagon Emergency KitGlucagon | 17 | $4,535 |
| Sucralfate | 31 | $4,520 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $42 | $70,81760 claims |
| AstraZenecaFarxiga | $129 | $52,87249 claims |
| Boehringer IngelheimJardiance, Tradjenta | $168 | $45,13945 claims |
| PfizerEliquis | $60 | $31,21760 claims |
| Johnson & JohnsonXarelto | $73 | $25,66850 claims |
| NovartisEntresto | $11 | $18,24222 claims |
| GSKTrelegy Ellipta | $88 | $14,77213 claims |
| Astellas Pharma US IncMyrbetriq | $37 | $13,83417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 275 geriatric medicine providers in Texas.
Other geriatric medicine in Houston
- George TaffetHouston$9K
- Adeeba AkhtarHouston$6K
- Anil ThakerHouston$4K
- Kathryn AgarwalHouston$4K
- Aimee GarciaHouston$3K
- Radhika HariharanHouston$3K
- Jerome WassersteinHouston$3K
- Sistla KrishnaHouston$2K
- Teresa AlbrightHouston$2K
- Rechelle AsirotHouston$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.